Editas Medicine
EDIT
187 hedge funds and large institutions have $1.02B invested in Editas Medicine in 2019 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 60 increasing their positions, 54 reducing their positions, and 24 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 54
10.1% more ownership
Funds ownership: 80.77% → 90.87% (+10%)
4% more capital invested
Capital invested by funds: $983M → $1.02B (+$40.8M)
3% less funds holding
Funds holding: 193 → 187 (-6)
25% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 24
47% less call options, than puts
Call options by funds: $8.12M | Put options by funds: $15.2M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$85.3M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$45.7M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$16.8M |
| 4 |
D.E. Shaw & Co
New York
|
+$8.78M |
| 5 |
BlackRock
New York
|
+$6.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16M |
| 2 |
State Street
Boston,
Massachusetts
|
-$14.2M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$4.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.61M |
| 5 |
WCM
Wildcat Capital Management
New York
|
-$4.59M |
EDIT Hedge Fund Activity: Q3 2019 in Review
187 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q3 2019, worth a combined $1.02B — up 4.1% from $983M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of EDIT and 18 opened new positions — a net loss of 6 holders — while 54 trimmed existing stakes and 60 added.
The largest buyer was Sumitomo Mitsui Trust Group, adding an estimated $85.3M. The largest seller was Fidelity Investments, cutting an estimated $16M.
- 187 institutional investors held Editas Medicine (EDIT) as of Q3 2019, down from 193 in Q2 2019.
- Funds reported $1.02B of Editas Medicine stock for Q3 2019, up 4.1% quarter-over-quarter.
- 18 funds opened new Editas Medicine positions in Q3 2019 and 24 closed out, a net change of -6 holders.
- The largest Editas Medicine buyer in Q3 2019 was Sumitomo Mitsui Trust Group, an estimated $85.3M added.
- The largest Editas Medicine seller in Q3 2019 was Fidelity Investments, an estimated $16M sold.
Based on aggregated 13F filings for Q3 2019.